Moleculin Biotech Management
Management criteria checks 3/4
Moleculin Biotech's CEO is Wally Klemp, appointed in Jul 2015, has a tenure of 8.83 years. total yearly compensation is $1.41M, comprised of 39.9% salary and 60.1% bonuses, including company stock and options. directly owns 2.04% of the company’s shares, worth $229.68K. The average tenure of the management team and the board of directors is 6.8 years and 7.4 years respectively.
Key information
Wally Klemp
Chief executive officer
US$1.4m
Total compensation
| CEO salary percentage | 39.9% |
| CEO tenure | 8.8yrs |
| CEO ownership | 2.0% |
| Management average tenure | 6.8yrs |
| Board average tenure | 7.4yrs |
Recent management updates
Recent updates
We're A Little Worried About Moleculin Biotech's (NASDAQ:MBRX) Cash Burn Rate
Dec 20
Can Moleculin Biotech (NASDAQ:MBRX) Afford To Invest In Growth?
Jul 14Is Moleculin Biotech (NASDAQ:MBRX) In A Good Position To Deliver On Growth Plans?
Feb 18Here's Why We're Watching Moleculin Biotech's (NASDAQ:MBRX) Cash Burn Situation
Nov 01Moleculin Biotech rises 7% as WP1096 compound selected for NIAID-funded animal studies
Sep 27Moleculin brain cancer therapy WP1122 gets FDA orphan drug status
Sep 06Here's Why We're Not Too Worried About Moleculin Biotech's (NASDAQ:MBRX) Cash Burn Situation
Jul 11Moleculin potential COVID drug WP1122 shows safety in preliminary data from phase 1a trial
Jul 08We Think Moleculin Biotech (NASDAQ:MBRX) Can Afford To Drive Business Growth
Mar 28We're Not Very Worried About Moleculin Biotech's (NASDAQ:MBRX) Cash Burn Rate
Dec 11We Think Moleculin Biotech (NASDAQ:MBRX) Can Afford To Drive Business Growth
Aug 18Moleculin Biotech to join Russell 2000 Index
Jun 15Is Moleculin Biotech (NASDAQ:MBRX) In A Good Position To Invest In Growth?
May 04Moleculin shares soar after promising Annamycin pre-clinical readout
Feb 02Moleculin Biotech under pressure on reverse stock split
Jan 29Here's Why We're A Bit Worried About Moleculin Biotech's (NASDAQ:MBRX) Cash Burn Situation
Jan 15Moleculin Bio's Annamycin an Orphan Drug in U.S. for soft tissue sarcomas
Dec 29Moleculin Bio on go with mid-stage study of Annamycin for lung metastases
Dec 17Moleculin Biotech's annamycin shows encouraging action in animal study
Nov 19Moleculin Biotech EPS beats by $0.04
Nov 13Moleculin further collaborates to advance WP1122 in COVID-19
Oct 29CEO Compensation Analysis
| Date | Total Compensation | Salary | Company Earnings |
|---|---|---|---|
| Dec 31 2023 | US$1m | US$565k | -US$30m |
| Sep 30 2023 | n/a | n/a | -US$26m |
| Jun 30 2023 | n/a | n/a | -US$29m |
| Mar 31 2023 | n/a | n/a | -US$30m |
| Dec 31 2022 | US$2m | US$565k | -US$29m |
| Sep 30 2022 | n/a | n/a | -US$25m |
| Jun 30 2022 | n/a | n/a | -US$21m |
| Mar 31 2022 | n/a | n/a | -US$18m |
| Dec 31 2021 | US$2m | US$538k | -US$16m |
| Sep 30 2021 | n/a | n/a | -US$16m |
| Jun 30 2021 | n/a | n/a | -US$15m |
| Mar 31 2021 | n/a | n/a | -US$21m |
| Dec 31 2020 | US$2m | US$500k | -US$17m |
| Sep 30 2020 | n/a | n/a | -US$19m |
| Jun 30 2020 | n/a | n/a | -US$19m |
| Mar 31 2020 | n/a | n/a | -US$10m |
| Dec 31 2019 | US$2m | US$625k | -US$13m |
| Sep 30 2019 | n/a | n/a | -US$12m |
| Jun 30 2019 | n/a | n/a | -US$10m |
| Mar 31 2019 | n/a | n/a | -US$14m |
| Dec 31 2018 | US$1m | US$403k | -US$12m |
| Sep 30 2018 | n/a | n/a | -US$12m |
| Jun 30 2018 | n/a | n/a | -US$13m |
| Mar 31 2018 | n/a | n/a | -US$11m |
| Dec 31 2017 | US$1m | US$325k | -US$10m |
Compensation vs Market: Wally's total compensation ($USD1.41M) is above average for companies of similar size in the US market ($USD667.63K).
Compensation vs Earnings: Wally's compensation has been consistent with company performance over the past year.
CEO
Wally Klemp (63 yo)
8.8yrs
Tenure
US$1,414,599
Compensation
Mr. Walter V. Klemp, also known as Wally, has been the Executive Chairman of Autonomix Medical, Inc. since joining in January 2022. He is President, Chief Executive Officer and Director of Zeno Corporation...
Leadership Team
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| Founder | 8.8yrs | US$1.41m | 2.04% $ 229.7k | |
| Executive VP & CFO | 7.8yrs | US$840.64k | 0.24% $ 27.2k | |
| Chief Scientific Officer | 6.8yrs | US$599.11k | 0.27% $ 30.4k | |
| Co-Founder | no data | no data | no data | |
| Senior Chief Medical Officer | 2.6yrs | no data | no data | |
| Chief Medical Officer of New Products | 6.5yrs | no data | no data | |
| European Chief Medical Officer | 2yrs | no data | no data | |
| Consultant | 6.8yrs | US$69.23k | no data | |
| Independent Advisor | no data | US$118.49k | no data |
6.8yrs
Average Tenure
68yo
Average Age
Experienced Management: MBRX's management team is seasoned and experienced (6.8 years average tenure).
Board Members
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| Founder | 8.8yrs | US$1.41m | 2.04% $ 229.7k | |
| Co-Founder | no data | no data | no data | |
| Independent Director | 7.9yrs | US$68.52k | 0% $ 0 | |
| Lead Independent Director | 6.8yrs | US$81.05k | 0% $ 0 | |
| Independent Director | 3.6yrs | US$63.52k | 0% $ 0 | |
| Independent Director | 7.9yrs | US$74.90k | 0.044% $ 4.9k | |
| Independent Director | 2.2yrs | US$47.15k | 0% $ 0 |
7.4yrs
Average Tenure
64yo
Average Age
Experienced Board: MBRX's board of directors are considered experienced (7.4 years average tenure).